Summary & Overview
HCPCS Level II J1700: Injection, Hydrocortisone Acetate, up to 25 mg
HCPCS Level II code J1700 denotes an injection of hydrocortisone acetate up to 25 mg, a corticosteroid used for anti-inflammatory and immunosuppressive treatment. This code matters nationally because injectable corticosteroids are commonly administered across outpatient clinics, physician offices, and ambulatory care settings; accurate coding affects claims processing, clinical documentation, and payer coverage determinations.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, common billing considerations, and what typical reimbursement and coverage discussions focus on for injectable corticosteroids. The publication summarizes benchmarks where available, highlights relevant policy updates affecting HCPCS Level II administration codes, and provides practical context for claims adjudication and documentation expectations.
The content is intended for a national audience and provides clarity on how J1700 is used in practice, what sites of service it most often appears in, and which payers typically handle claims for this injectable medication. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1700 describes an injection of hydrocortisone acetate, up to 25 mg. This service represents administration of a corticosteroid preparation intended for anti-inflammatory or immunosuppressive purposes.
-
Service type: Injection/therapeutic medication administration
-
Typical site of service: Outpatient clinic, physician office, or ambulatory care setting where injectable corticosteroid therapies are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a localized inflammatory skin nodule presents to an outpatient dermatology clinic for corticosteroid injection. The clinician diagnoses a small, symptomatic subcutaneous inflammatory lesion or keloid scar causing pain and restricted movement. After obtaining informed consent, the clinician prepares a syringe with hydrocortisone acetate up to 25 mg (J1700). The procedure is performed in a procedure room or clinic exam room: the skin is cleansed, local anesthesia is applied if needed, and the corticosteroid is injected directly into the lesion using aseptic technique. The patient is observed briefly for immediate adverse reaction, given post-care instructions, and scheduled for follow-up to assess response and need for repeat injection. Typical site of service is an outpatient clinic, dermatology office, wound care center, or ambulatory surgery center for simple injections; inpatient administration is uncommon for this formulation and dose range.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Routine reporting when no modifier applies |
22 | Increased procedural services |